TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6393443

Group type: EXPERIMENTAL
Intervention: B-diet plus 3 X 20 g fresh onion per day
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: B-diet plus 3 X 200 g green beans per day
Number of subjects: 260

Group type: COMPARATOR
Intervention: B-diet
Number of subjects: 260
Study: 27503325

Group type: EXPERIMENTAL
Intervention: Reloadable wireless bank cards
Number of subjects: 600

Group type: COMPARATOR
Intervention: Cash payment
Number of subjects: 600
Study: 28799964

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham Block (SHAM)
Number of subjects: 63
Study: 26638911

Group type: EXPERIMENTAL
Intervention: 500 mg of resveratrol plus 10 mg of piperine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24454949

Group type: EXPERIMENTAL
Intervention: 24-hour fast (FASTED)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal feeding (FED)
Number of subjects: 15
Study: 22045316

Group type: EXPERIMENTAL
Intervention: DHEA (130 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19096087

Group type: EXPERIMENTAL
Intervention: Prognostic score based on selected risk factors
Number of subjects: 4142

Group type: EXPERIMENTAL
Intervention: Risk factors included: body mass index <18.5 kg/m2 (2 points), diabetes (1 point), congestive heart failure stages III to IV (2 points), peripheral vascular disease stages III to IV (2 points), dysrhythmia (1 point), active malignancy (1 point), severe behavioural disorder (2 points), total dependency for transfers (3 points), unplanned dialysis (2 points)
Number of subjects: 4142
Study: 17413118

Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isoflavone-depleted soy protein
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Soy protein with enriched isoflavones
Number of subjects: 11
Study: 15290200

Group type: EXPERIMENTAL
Intervention: TGDc‐01 tonometer
Number of subjects: 100

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 100
Study: 12170429

Group type: EXPERIMENTAL
Intervention: Bendamustine/prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melphalan/prednisolone
Number of subjects: 0
Study: 10094425

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard monotherapy (Carbamazepine or Phenytoin)
Number of subjects: 0
Study: 7845426

Group type: EXPERIMENTAL
Intervention: Debulking surgery
Number of subjects: 278

Group type: COMPARATOR
Intervention: No surgery (control)
Number of subjects: 278
Study: 2347116

Group type: EXPERIMENTAL
Intervention: Low alcohol beer (reduced weekly alcohol intake from 481 +/- 47 mL to 52 +/- 5 mL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moderate exercise programme (three 30 min sessions per week of stationary cycling at 60-70% maximum workload)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Light exercise programme (pedalling against zero or minimal resistance)
Number of subjects: 72
Study: 382878

Group type: EXPERIMENTAL
Intervention: buspirone (N = 18)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: diazepam (N = 20)
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo (N = 18)
Number of subjects: 56
Study: 31980448

Group type: EXPERIMENTAL
Intervention: Addition of azathioprine (AZA) to second anti-TNF therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Monotherapy with second anti-TNF (no AZA)
Number of subjects: 90
Study: 30431709

Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-releasing implants (mometasone furoate, 370 μg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (contralateral side without implant)
Number of subjects: 160
Study: 30026614

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Cancer-related Insomnia (BBT-CI)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy Eating Education Learning (HEAL)
Number of subjects: 71
Study: 27054583

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Patient education alone
Number of subjects: 121
Study: 25015566

Group type: EXPERIMENTAL
Intervention: ePULab (web-based e-learning tool)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional face-to-face instruction
Number of subjects: 0
Study: 21628601

Group type: EXPERIMENTAL
Intervention: Prasugrel active metabolite (pras-AM) exposure
Number of subjects: 1159
Study: 20617484

Group type: COMPARATOR
Intervention: Concurrent training (CG, n=8)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Strength training (SG, n=8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Endurance training (EG, n=7)
Number of subjects: 23
Study: 17975981

Group type: EXPERIMENTAL
Intervention: LDI‐100 (1.35 ng of BCG and 2 units of hCG, SC, q 24 h)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Vinblastine (2 mg/m2, IV, q 1 wk)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: LDI‐100
Number of subjects: 95
Study: 15794385

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no IVMP)
Number of subjects: 19
Study: 12425728

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched chocolate (1.8 g unesterified phytosterols/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo chocolate
Number of subjects: 70
Study: 9928724

Group type: EXPERIMENTAL
Intervention: ZDV + ddI + nevirapine
Number of subjects: 68

Group type: COMPARATOR
Intervention: ZDV + ddI
Number of subjects: 68
Study: 7540058

Group type: EXPERIMENTAL
Intervention: High-dose magnesium regimen (4.2 +/- 0.7 g magnesium sulfate before bypass, followed by 11.9 +/- 2.8 g magnesium chloride until the first postoperative morning, and 5.5 +/- 1.0 g until the second postoperative morning)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low-dose magnesium regimen (2.9 +/- 0.5 g magnesium sulfate at the first postoperative morning, and 1.4 +/- 0.1 g at the second postoperative morning)
Number of subjects: 81
Study: 2182736

Group type: EXPERIMENTAL
Intervention: rhEpo (600 U/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 6110626

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31012067

Group type: EXPERIMENTAL
Intervention: Nocturnal noise level and landcover diversity index
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Landcover heterogeneity
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Noise intensity
Number of subjects: 65
Study: 29920521

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLL) applied at auriculotherapy points
Number of subjects: 42

Group type: COMPARATOR
Intervention: Simulation of LLL treatment (control group)
Number of subjects: 42
Study: 27431736

Group type: EXPERIMENTAL
Intervention: IB1 topical protective lotion
Number of subjects: 144
Study: 24590773

Group type: EXPERIMENTAL
Intervention: Exemestane (5 years)
Number of subjects: 737
Study: 22017519

Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Cladribine 5.25 mg/kg
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (both doses)
Number of subjects: 1326
Study: 19886838

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 126

Group type: COMPARATOR
Intervention: IFN-gamma, IL-2, and IL-12 responses
Number of subjects: 126
Study: 17261234

Group type: EXPERIMENTAL
Intervention: Antibiotic therapies based on stratification by disease severity
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Antibiotic therapies utilized in the trial (specific antibiotics not mentioned)
Number of subjects: 659
Study: 15813496

Group type: EXPERIMENTAL
Intervention: Thematically induced arousal through empathy
Number of subjects: 0
Study: 11255901

Group type: COMPARATOR
Intervention: Immediate prescription (92 patients)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Delayed prescription (99 patients)
Number of subjects: 191
Study: 9734940

Group type: EXPERIMENTAL
Intervention: 30 IU/m2 somatropin per week as daily subcutaneous injections
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (non-consent group)
Number of subjects: 10
Study: 7833104

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 171

Group type: COMPARATOR
Intervention: Thiotepa
Number of subjects: 171
Study: 3369324

Group type: EXPERIMENTAL
Intervention: Detoxification fear group (N = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-fear group (N = 8)
Number of subjects: 16
Study: 28926855

Group type: EXPERIMENTAL
Intervention: Once-daily Fluticasone Furoate/Vilanterole (FF/VI) 200/25 µg via ElliptaTM DPI
Number of subjects: 18

Group type: COMPARATOR
Intervention: Twice-daily Fluticasone Propionate/Salmeterol (FP/SAL) 500/50 µg via DiskusTM DPI
Number of subjects: 18
Study: 26805750

Group type: EXPERIMENTAL
Intervention: CGA-based care (Intervention Group)
Number of subjects: 382
Study: 24992553

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg daily
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 23033391

Group type: EXPERIMENTAL
Intervention: Spectral Domain Optical Coherence Tomography (SD-OCT)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Time Domain Optical Coherence Tomography (TD-OCT)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: SD-OCT and TD-OCT
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: SD-OCT
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: TD-OCT
Number of subjects: 186
Study: 19895912

Group type: EXPERIMENTAL
Intervention: High calcium milk drink with added vitamin D, magnesium and zinc (HCM)
Number of subjects: 2
Study: 17804023

Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left PPR
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cathodal stimulation of left PPR
Number of subjects: 15

Group type: COMPARATOR
Intervention: Anodal stimulation of the homologous region of the right hemisphere
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 16227798

Group type: EXPERIMENTAL
Intervention: Experimental condition (leaders of 25 networks attended a nine-session program)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 276
Study: 12871541

Group type: EXPERIMENTAL
Intervention: Antidote administration (specific antidotes)
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Major hemorrhage
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Vitamin K
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Protamin sulfate
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Antidote usage comparison
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Vitamin K administration
Number of subjects: 1877
Study: 10692930

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (2 drops of 0.3% ophthalmic solution every 30 min for 3 h, then every 60 min for the next 3 h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral ciprofloxacin (single dose of 1000 mg 6 h before surgery)
Number of subjects: 34
Study: 8836872

Group type: EXPERIMENTAL
Intervention: Beta-carotene (31.4 mg/day) plus D-alpha-tocopherol acetate (720 IU/day) supplements
Number of subjects: 7
Study: 8354735

Group type: EXPERIMENTAL
Intervention: Nortriptyline (mean plasma level 85.3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (in maintenance therapy)
Number of subjects: 48
Study: 3524511

Group type: EXPERIMENTAL
Intervention: Cefoxitin plus tobramycin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Clindamycin plus tobramycin
Number of subjects: 96
Study: 30022578

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (AHSCT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 10
Study: 26909786

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) + Total Intravenous Anesthesia (TIVA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 23
Study: 25807408

Group type: EXPERIMENTAL
Intervention: Muscle protein fractional synthesis rate measured at 1, 2, 4 weeks, 6, 12, and 24 months after burn injury.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Muscle protein fractional synthesis rate in boys, children older than 3 years, and burns greater than 80% TBSA.
Number of subjects: 87
Study: 23631396

Group type: EXPERIMENTAL
Intervention: Prepackaged all‐inclusive kit
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard kit
Number of subjects: 30
Study: 21055963

Group type: EXPERIMENTAL
Intervention: High COP group (5% albumin in priming, COP maintained above 18 mmHg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard COP group (0.5 g/kg albumin in priming, COP target at 15 mmHg)
Number of subjects: 70
Study: 19776719

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0
Study: 16567158

Group type: EXPERIMENTAL
Intervention: TV group (children watched a 22‐minute cartoon video on TV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: no TV group (children did not watch TV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TV group (children who watched more daily hours of TV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TV group (children with a higher frequency of meals eaten in front of the TV at home)
Number of subjects: 24
Study: 12627041

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day for 21 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no tamoxifen)
Number of subjects: 40
Study: 10689253

Group type: EXPERIMENTAL
Intervention: Infusion of contrast (1.3 mL in 50 mL normal saline initially at 4.0 mL/min)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bolus injections of contrast (10 microL/kg each over a period of 30 to 60 seconds)
Number of subjects: 64
Study: 7503004

Group type: EXPERIMENTAL
Intervention: Oral propafenone 600 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study: 2032708

Group type: EXPERIMENTAL
Intervention: Tego 103G biocide soak
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo soak
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Miconazole therapy
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Oral nystan
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: General factors
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Oral yeast carriage rate in women
Number of subjects: 186
Study: 7086742

Group type: EXPERIMENTAL
Intervention: Behavioural treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: No-treatment (control)
Number of subjects: 50
Study: 30427246

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BRJ) 140 mL daily (∼800 mg/d nitrate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BRJ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA)
Number of subjects: 10
Study: 29178772

Group type: EXPERIMENTAL
Intervention: Alkaline peroxide (AP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (SH)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (C) - distilled water
Number of subjects: 32
Study: 25499536

Group type: EXPERIMENTAL
Intervention: Condensed protocol by genetic counselors (CP-GC)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Condensed protocol by physicians (CP-MD)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Standard protocol by genetic counselors (SP-GC)
Number of subjects: 343
Study: 23466709

Group type: EXPERIMENTAL
Intervention: S boulardii (1 g/day)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: S boulardii
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: S boulardii (in nonsmokers)
Number of subjects: 165
Study: 21309806

Group type: EXPERIMENTAL
Intervention: ONSI‐56 material lenses
Number of subjects: 28

Group type: COMPARATOR
Intervention: Boston XO material lenses
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Miraflow cleaner
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Boston Advance cleaner
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Preference for lenses
Number of subjects: 28
Study: 19685113

Group type: EXPERIMENTAL
Intervention: 20‐gauge catheter (20G)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 22‐gauge catheter (22G)
Number of subjects: 30
Study: 16730541

Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy (TWT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bipolar electrocautery tonsillectomy (BET)
Number of subjects: 150
Study: 15584820

Group type: EXPERIMENTAL
Intervention: Panoramic search method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory search
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forced memory trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choice between vision and memory
Number of subjects: 0
Study: 11376827

Group type: EXPERIMENTAL
Intervention: enalapril (10-20 mg per day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: losartan (50-100 mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: baseline untreated hypertensive patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: enalapril or losartan
Number of subjects: 40
Study: 9401542

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment at a dose of 0.1 IU/kg/day for 2 years (group A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Growth hormone treatment at a dose of 0.2 IU/kg/day for the second year (group B)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 27
Study: 7811026

Group type: EXPERIMENTAL
Intervention: Ensure (enteral feeding product)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Water
Number of subjects: 13
Study: 3417845

Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3/day
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3/day
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 142
Study: 31634897

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31618598

Group type: EXPERIMENTAL
Intervention: 4 bouts of 5-min counterweighted, single-leg cycling
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1 bout of 5-min counterweighted, single-leg cycling
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison between 4-bout and 1-bout groups
Number of subjects: 9
Study: 28325123

Group type: EXPERIMENTAL
Intervention: 5% menthol gel applied to the skin over the quadriceps muscle
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (Adult Placebo group)
Number of subjects: 42
Study: 25460860

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Change in LVESVi
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Other remodeling parameters (left ventricular end-diastolic volume index and ejection fraction)
Number of subjects: 353
Study: 23216900

Group type: EXPERIMENTAL
Intervention: Questionnaire on Pediatric Gastrointestinal Symptoms (QPGS‐RIII)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Parent and child reports
Number of subjects: 135

Group type: COMPARATOR
Intervention: QPGS‐RIII
Number of subjects: 135

Group type: COMPARATOR
Intervention: Diaries
Number of subjects: 135
Study: 21249489

Group type: EXPERIMENTAL
Intervention: Diabetogenic VPS13C/C2CD4A/C2CD4B rs7172432 A allele
Number of subjects: 5722
Study: 18481578

Group type: EXPERIMENTAL
Intervention: Total-etch adhesive system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-etch adhesive system
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beveled margins
Number of subjects: 60
Study: 16575035

Group type: EXPERIMENTAL
Intervention: Betamethasone 8 mg iv
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Normal saline 2 mL (placebo)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg iv
Number of subjects: 9
Study: 14736355

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 29
Study: 10910857

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% (Group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.75% (Group R)
Number of subjects: 180

Group type: COMPARATOR
Intervention: saline (Group S)
Number of subjects: 180
Study: 8959423

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Time Interval Condition (TIC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tapping Alternate Phalanges (TAP)
Number of subjects: 18
Study: 1525903

Group type: EXPERIMENTAL
Intervention: Anxiolytics and Mg-lactate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anxiolitics and placebo
Number of subjects: 20
Study: 3897612

Group type: EXPERIMENTAL
Intervention: 375 mg of S6472 given orally before a meal
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 375 mg of S6472 given orally after a light meal
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 375 mg of S6472 given orally after a usual meal
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 750 to 1,500 mg/day of S6472
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: S6472
Number of subjects: 62
Study: 30244288

Group type: EXPERIMENTAL
Intervention: Blood flow restricted resistance exercise (BFR‐RE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study: 26655188

Group type: EXPERIMENTAL
Intervention: rTMS on left DLPFC
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (pharmacological agents)
Number of subjects: 32
Study: 25461205

Group type: EXPERIMENTAL
Intervention: USL255 (topiramate)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 22353512

Group type: EXPERIMENTAL
Intervention: Fujinon EC‐450 (FS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Olympus GIF‐Q260 (OS)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both FS and OS
Number of subjects: 86